机构：[a]Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China[b]Southern Medical University, Guangzhou, Guangdong, China[c]Department of Dermatovenereology, Foshan Women and Children Hospital, Foshan, Guangdong, China[d]Department of Gynecology, The First People’s Hospital of Huizhou City, Huizhou, Guangdong, China[e]Department of Gynecology Oncology, The Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China[f]Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China[g]Guangzhou Medical University, Guangzhou, Guangdong, China[h]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China
To investigate FOXO1 expression in epithelial ovarian cancer (EOC), and to explore its correlation with clinicopathological parameters and prognosis of EOC.
Two hundred and sixteen cases of paraffin-embedded EOC and 41 paratumor tissues from 2009 to 2017 that had been pathologically confirmed at the memorial hospital of Sun Yat-sen University were included in this study, and the expression of FOXO1 was performed by immunohistochemistry using a polyclonal antibody specific for FOXO1.
FOXO1 protein expression is associated with Recurrence free and overall survival in EOC patients; In addition, FOXO1 expression is associated with age, FIGO stage, intraperitoneal metastasis, intestinal metastasis, vital status, intraperitoneal recurrence and differentiation grade; Moreover, in a multivariate model FOXO1 overexpression was an independent predictor of poor survival in EOC.
FOXO1 may play a candidate oncogenic role in EOC, and FOXO1 is a useful independent prognostic marker in EOC, and it may provide a candidate target therapy in future.
基金：
This study was supported by the Guangdong Provincial Medical Research Fund (grant no. A2019096), the
President funds of Integrated Hospital of Traditional
Chinese Medicine, Southern Medical University (No. 1201902001; No. 1201901002), the High-Level Academic Talent Training Program of Guangzhou Medical University (No. B185004083; No. B195001100),
Guangzhou Science and Information Bureau Item
(grant no. 201904010013), Natural Science Founda294
tion of Guangdong Province (grant no. 2018A0303130
180) and Hospital achievement transformation and
Cultivation Project (grant no. ZH201812).
第一作者机构：[a]Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China[b]Southern Medical University, Guangzhou, Guangdong, China
共同第一作者：
通讯作者：
通讯机构：[f]Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China[g]Guangzhou Medical University, Guangzhou, Guangdong, China[h]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China[*1]Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.[*2]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 13 Shiliugang ST, Guangzhou, Guangdong, 510315, China
推荐引用方式(GB/T 7714)：
Longyang Liu,Juanjuan Yi,Jianhuan Yuan,et al.FOXO1 overexpression is correlated with poor prognosis in epithelial ovarian cancer.[J].CANCER BIOMARKERS.2020,28(1):1-8.doi:10.3233/CBM-182119.
APA：
Longyang Liu,Juanjuan Yi,Jianhuan Yuan,Tingting Yao,Zhongqiu Lin...&Zhaoyang Zeng.(2020).FOXO1 overexpression is correlated with poor prognosis in epithelial ovarian cancer..CANCER BIOMARKERS,28,(1)
MLA：
Longyang Liu,et al."FOXO1 overexpression is correlated with poor prognosis in epithelial ovarian cancer.".CANCER BIOMARKERS 28..1(2020):1-8
